These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8695352

  • 1. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI, Odell DE, Kelland LR.
    Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ, Kelland LR.
    Cancer Res; 1994 Dec 01; 54(23):6194-200. PubMed ID: 7954466
    [Abstract] [Full Text] [Related]

  • 3. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
    Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CF, Murrer BA, Harrap KR.
    Cancer Chemother Pharmacol; 1996 Dec 01; 38(2):155-62. PubMed ID: 8616906
    [Abstract] [Full Text] [Related]

  • 4. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR.
    Anticancer Res; 1996 Dec 01; 16(4A):1857-62. PubMed ID: 8712713
    [Abstract] [Full Text] [Related]

  • 5. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep 01; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

  • 6. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Aug 01; 68(2):240-50. PubMed ID: 8347478
    [Abstract] [Full Text] [Related]

  • 7. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
    Mellish KJ, Barnard CF, Murrer BA, Kelland LR.
    Int J Cancer; 1995 Sep 15; 62(6):717-23. PubMed ID: 7558420
    [Abstract] [Full Text] [Related]

  • 8. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 9. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 01; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 10. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
    Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C.
    Biochem Pharmacol; 2002 Jun 01; 63(11):1989-96. PubMed ID: 12093475
    [Abstract] [Full Text] [Related]

  • 11. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.
    Poon GK, Raynaud FI, Mistry P, Odell DE, Kelland LR, Harrap KR, Barnard CF, Murrer BA.
    J Chromatogr A; 1995 Sep 29; 712(1):61-6. PubMed ID: 8556156
    [Abstract] [Full Text] [Related]

  • 12. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
    Sharp SY, Smith V, Hobbs S, Kelland LR.
    Br J Cancer; 1998 Jul 29; 78(2):175-80. PubMed ID: 9683290
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
    Kurata T, Tamura T, Sasaki Y, Fujii H, Negoro S, Fukuoka M, Saijo N.
    Jpn J Clin Oncol; 2000 Sep 29; 30(9):377-84. PubMed ID: 11095134
    [Abstract] [Full Text] [Related]

  • 14. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR.
    Cancer Res; 1994 Aug 01; 54(15):4118-22. PubMed ID: 8033145
    [Abstract] [Full Text] [Related]

  • 15. Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.
    Ando Y, Shimizu T, Nakamura K, Mushiroda T, Nakagawa T, Kodama T, Kamataki T.
    Br J Cancer; 1998 Nov 01; 78(9):1170-4. PubMed ID: 9820175
    [Abstract] [Full Text] [Related]

  • 16. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR.
    Br J Cancer; 1991 Aug 01; 64(2):215-20. PubMed ID: 1892748
    [Abstract] [Full Text] [Related]

  • 17. Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates.
    Poon GK, Mistry P, Raynaud FI, Harrap KR, Murrer BA, Barnard CF.
    J Pharm Biomed Anal; 1995 Nov 01; 13(12):1493-8. PubMed ID: 8788134
    [Abstract] [Full Text] [Related]

  • 18. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR.
    Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660
    [Abstract] [Full Text] [Related]

  • 19. Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo.
    Xing B, Zhu H, Wang Y, Tang W.
    Biometals; 2000 Sep 15; 13(3):203-8. PubMed ID: 11127891
    [Abstract] [Full Text] [Related]

  • 20. Oral platinum analogue JM216, a radiosensitizer in oxic murine cells.
    van de Vaart PJ, Klaren HM, Hofland I, Begg AC.
    Int J Radiat Biol; 1997 Dec 15; 72(6):675-83. PubMed ID: 9416790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.